CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $136.28M, lower than 95% of all stocks globally
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
As of FY2025 (year ended April 30, 2025). Newer annual figures aren't yet on file.
Financials view
Market Capitalization
127.53MGBP136.28M · vs all stocks (USD)
Revenue (TTM)
4.71MGBP6.36M · vs all stocks (USD)
Profit Margin
-116.98%vs Biotechnology peers
Beta
0.6890xvs all stocks
52-Week Change
-4.28%vs all stocks
Forward Annual Dividend Yield
0.00%vs all stocks
Market Capitalization
127.53MGBP136.28M · vs all stocks (USD)
Enterprise Value
105.68MGBP149.03M · vs all stocks (USD)
Forward P/E
-8.70xvs Biotechnology peers
Price to Sales (TTM)
27.07xvs Biotechnology peers
Enterprise to Revenue
22.43xvs Biotechnology peers
Enterprise to EBITDA
-8.15xvs Biotechnology peers
Profit Margin
-116.98%vs Biotechnology peers
Operating Margin
-283.34%vs Biotechnology peers
Return on Assets (TTM)
-52.17%vs Biotechnology peers
Revenue (TTM)
4.71MGBP6.36M · vs all stocks (USD)
Revenue per Share (TTM)
0.0050GBPUpdated Oct 8, 2026Gross Profit (TTM)
4.47MGBP6.04M · vs all stocks (USD)
EBITDA (TTM)
-12.96MGBP-17.51M · vs all stocks (USD)
Net Income (TTM)
-5.51MGBP-7.44M · vs all stocks (USD)
Operating Cash Flow (TTM)
-8.65MGBP-11.68M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-17.12MGBP-23.12M · vs all stocks (USD)
Forward Annual Dividend Yield
0.00%vs all stocks
Trailing Annual Dividend Rate
0.00GBPUpdated Oct 8, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Revenue
4.71MGBPFY2025 · Apr 30, 2025Cost of Goods Sold
238.00KGBPFY2025 · Apr 30, 2025Gross Profit
4.47MGBPFY2025 · Apr 30, 2025Operating Income
-15.00MGBP-20.26M · vs all stocks (USD)
Pre-tax Income
-15.30MGBPFY2025 · Apr 30, 2025Income Tax Expense
-3.03MGBPFY2025 · Apr 30, 2025Net Income
-12.27MGBPFY2025 · Apr 30, 2025EBIT
-13.59MGBPFY2025 · Apr 30, 2025EBITDA (Income Statement)
-13.79MGBPFY2025 · Apr 30, 2025Research & Development
14.69MGBPFY2025 · Apr 30, 2025Selling, General & Administrative
4.79MGBPFY2025 · Apr 30, 2025Non-operating Interest Income
336.00KGBPFY2025 · Apr 30, 2025Non-operating Interest Expense
1.72MGBPFY2025 · Apr 30, 2025EPS (Basic)
-0.0126GBPFY2025 · Apr 30, 2025EPS (Diluted)
-0.0126GBPFY2025 · Apr 30, 2025Basic Shares Outstanding
970.32MSharesFY2025 · Apr 30, 2025Diluted Shares Outstanding
970.32MSharesFY2025 · Apr 30, 2025Preferred Stock Dividends
0.00GBPFY2025 · Apr 30, 2025Operating Cash Flow
-12.87MGBPFY2025 · Apr 30, 2025Free Cash Flow
-12.88MGBPFY2025 · Apr 30, 2025Cash & Cash Equivalents (End of Period)
16.89MGBPFY2025 · Apr 30, 2025Starting Profit (CF Statement)
-15.30MGBPFY2025 · Apr 30, 2025Stock-based Compensation
1.36MGBPFY2025 · Apr 30, 2025Other Non-cash Items
331.00KGBPFY2025 · Apr 30, 2025Change in Accounts Receivable (CF)
747.00KGBPFY2025 · Apr 30, 2025Capital Expenditures
-14.00KGBPFY2025 · Apr 30, 2025Net Intangibles (CF)
-1.52MGBPFY2025 · Apr 30, 2025Net Investing Cash Flow
-14.00KGBPFY2025 · Apr 30, 2025Long-term Debt Payments
-450.00KGBPFY2025 · Apr 30, 2025Net Financing Cash Flow
10.83MGBPFY2025 · Apr 30, 2025Shares Outstanding
1.04BSharesUpdated Oct 8, 2026Float Shares
648.32MSharesUpdated Oct 8, 2026% Held by Insiders
3.13%vs all stocks
% Held by Institutions
38.03%vs all stocks
Total Cash (MRQ)
8.57MGBP11.58M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.0080GBPUpdated Oct 8, 2026Total Debt (MRQ)
16.18MGBP21.85M · vs all stocks (USD)
Current Ratio (MRQ)
0.5590xvs Biotechnology peers
Book Value per Share (MRQ)
-0.0080GBPUpdated Oct 8, 2026Total Assets
23.09MGBP31.18M · vs all stocks (USD)
Total Current Assets
20.62MGBPFY2025 · Apr 30, 2025Total Liabilities
26.93MGBPFY2025 · Apr 30, 2025Total Non-current Assets
2.47MGBPFY2025 · Apr 30, 2025Total Non-current Liabilities
123.00KGBPFY2025 · Apr 30, 2025Total Current Liabilities
26.80MGBPFY2025 · Apr 30, 2025Cash & Cash Equivalents
16.89MGBPFY2025 · Apr 30, 2025Accounts Payable
606.00KGBPFY2025 · Apr 30, 2025Short-term Debt
16.14MGBPFY2025 · Apr 30, 2025Long-term Debt
123.00KGBPFY2025 · Apr 30, 2025Common Stock (Book)
1.04MGBPFY2025 · Apr 30, 2025Retained Earnings
-96.46MGBPFY2025 · Apr 30, 2025Total Shareholders' Equity
-3.83MGBP-5.18M · vs all stocks (USD)
52-Week Low
9.10GBXUpdated Oct 8, 202652-Week High
29.50GBXUpdated Oct 8, 202652-Week Change
-4.28%vs all stocks
Beta
0.6890xvs all stocks
50-Day MA
9.68GBXUpdated Oct 8, 2026200-Day MA
13.58GBXUpdated Oct 8, 2026Avg 10-Day Volume
1.49MSharesUpdated Oct 8, 2026Avg 30-Day Volume
2.10MSharesUpdated Oct 8, 2026Diluted EPS (TTM)
-0.0100GBPUpdated Oct 8, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $136.28M, lower than 95% of all stocks globallySignificant
Market cap (USD): 136,276,309.507Global P5: 267,497,161.457
Revenue is $6.36M, lower than 95% of all stocks globallySignificant
Revenue (USD): 6,362,346.83Global P5: 36,021,613.518
Companies that share the same coordination system — how they create, deliver, or capture value.
Curacle Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Compass Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Perspective Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Futurechem Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Avidity Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Pyridam Farma Tbk.
Tier 1ProductionApproval-Gated PipelineRuleFlow
CVRx, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Neumora Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Sutro Biopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
3Billion Inc.
Tier 1ProductionApproval-Gated PipelineSenseMakingRule
Companies that share active interpretations — structural patterns currently present in both stocks.
ServiceNow, Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Intellia Therapeutics Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Ondas Holdings Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC